Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Couldwell et al. present a timely and clinically significant analysis of the reproductive implications of GLP1 receptor agonist therapy. Their review in The Journal of Clinical Endocrinology & Metabolism highlights an evolving area of practice that intersects metabolic and reproductive endocrinology -- a frontier that increasingly influences patient care for reproductive-age women with obesity or polycystic ovary syndrome (PCOS).”
“GLP1 agonists may improve reproductive function both in men and women, in addition to but independently of their well-recognized weight-loss benefits for patients with obesity. This is the key take home from a literature review, which appears in The Journal of Clinical Endocrinology & Metabolism.”
Review analyzes the effects of GLP1 agonists on reproductive health amidst obesity-related challenges, indicating caution.
Obesity, in animals and humans, is associated with male and female reproductive dysfunction. Elucidating the mechanisms by which excessive weight affects reproduction and proving that weight loss improves reproductive function has been difficult. Data in animals and humans demonstrate improvements in reproductive function after weight loss, achieved with or without glucagon-like peptide 1 (GLP1) agonists. In preclinical studies there is evidence that GLP1 agonists have direct effects on the hypothalamus to stimulate luteinizing hormone (LH) secretion and direct beneficial effects on the gonads and the endometrium. Whether GLP-1 agonists provide an added direct beneficial effect on reproductive organs in humans, beyond the benefits mediated by weight loss, remains unclear. However, consideration of GLP1 agonists for the treatment for obesity-associated reproductive dysfunction requires caution, as any weight loss during pregnancy is associated with adverse fetal outcomes, and preclinical studies indicate fetal toxicity of the GLP1 agonist class. Here, we review the available preclinical and clinical evidence of the effects of GLP-1 agonists on human reproductive health, suggest a therapeutic strategy, and list the needs for future research.
No takes yet. Share an insight, caveat, or question.
Couldwell et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: